Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

Abstract Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy. The study cohort included 4763 patients with diagnosed advanced HCC who received sorafe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shou-Sheng Chu, Yu-Hsuan Kuo, Wen-Shan Liu, Shih-Chang Wang, Chung-Han Ho, Yi-Chen Chen, Ching-Chieh Yang, Hung-Chang Wu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/024fcee6fe3d4b1b8d21bbf35167f3b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:024fcee6fe3d4b1b8d21bbf35167f3b2
record_format	dspace
spelling	oai:doaj.org-article:024fcee6fe3d4b1b8d21bbf35167f3b22021-12-02T14:12:46ZEffect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study10.1038/s41598-021-81176-w2045-2322https://doaj.org/article/024fcee6fe3d4b1b8d21bbf35167f3b22021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81176-whttps://doaj.org/toc/2045-2322Abstract Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy. The study cohort included 4763 patients with diagnosed advanced HCC who received sorafenib between January 2012 and December 2015, as reported in medical records in the Taiwan Cancer Registry database. The effect of sorafenib with or without radiotherapy on survival was calculated using the Kaplan–Meier method and compared using the log-rank test. A Cox proportional hazards model was used for multivariate analysis. Patients receiving sorafenib plus radiotherapy had greater 1-year survival than did those receiving sorafenib alone (P < 0.001). Uni- and multivariate analyses also showed that radiotherapy increased survival after adjusting for confounders (adjusted HR 0.57; 95% CI 0.51–0.63). Further stratified analysis according to the timing of radiotherapy relative to sorafenib treatment revealed that patients who underwent radiotherapy after sorafenib had greater 1-year survival than did those undergoing radiotherapy within sorafenib use or sorafenib alone (adjusted HR 0.39; 95% CI 0.27–0.54). Combined treatment with sorafenib and radiotherapy results in greater HCC patient survival and should be considered an option for treating this challenging disease.Shou-Sheng ChuYu-Hsuan KuoWen-Shan LiuShih-Chang WangChung-Han HoYi-Chen ChenChing-Chieh YangHung-Chang WuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shou-Sheng Chu Yu-Hsuan Kuo Wen-Shan Liu Shih-Chang Wang Chung-Han Ho Yi-Chen Chen Ching-Chieh Yang Hung-Chang Wu Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
description	Abstract Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy. The study cohort included 4763 patients with diagnosed advanced HCC who received sorafenib between January 2012 and December 2015, as reported in medical records in the Taiwan Cancer Registry database. The effect of sorafenib with or without radiotherapy on survival was calculated using the Kaplan–Meier method and compared using the log-rank test. A Cox proportional hazards model was used for multivariate analysis. Patients receiving sorafenib plus radiotherapy had greater 1-year survival than did those receiving sorafenib alone (P < 0.001). Uni- and multivariate analyses also showed that radiotherapy increased survival after adjusting for confounders (adjusted HR 0.57; 95% CI 0.51–0.63). Further stratified analysis according to the timing of radiotherapy relative to sorafenib treatment revealed that patients who underwent radiotherapy after sorafenib had greater 1-year survival than did those undergoing radiotherapy within sorafenib use or sorafenib alone (adjusted HR 0.39; 95% CI 0.27–0.54). Combined treatment with sorafenib and radiotherapy results in greater HCC patient survival and should be considered an option for treating this challenging disease.
format	article
author	Shou-Sheng Chu Yu-Hsuan Kuo Wen-Shan Liu Shih-Chang Wang Chung-Han Ho Yi-Chen Chen Ching-Chieh Yang Hung-Chang Wu
author_facet	Shou-Sheng Chu Yu-Hsuan Kuo Wen-Shan Liu Shih-Chang Wang Chung-Han Ho Yi-Chen Chen Ching-Chieh Yang Hung-Chang Wu
author_sort	Shou-Sheng Chu
title	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
title_short	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
title_full	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
title_fullStr	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
title_full_unstemmed	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
title_sort	effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/024fcee6fe3d4b1b8d21bbf35167f3b2
work_keys_str_mv	AT shoushengchu effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy AT yuhsuankuo effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy AT wenshanliu effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy AT shihchangwang effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy AT chunghanho effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy AT yichenchen effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy AT chingchiehyang effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy AT hungchangwu effectofradiotherapyonsurvivalinadvancedhepatocellularcarcinomapatientstreatedwithsorafenibanationwidecancerregistrybasedstudy
_version_	1718391763976060928

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

Ejemplares similares